A new cut point for Unfavorable Intermediate-Risk patients

The GPS assay stratifies unfavorable intermediate-risk patients into two distinct groups with highly differing long-term outcomes

GPS ≤40 vs >40

GPS The GPS cut point of 40 stratifies Unfavorable Intermediate-Risk patients into two distinct subsets of patients with highly differing long-term outcomes.1

Unfavorable Intermediate-Risk Patients1,2


The Oncotype DX test reduces risks of over and undertreatment2


73% of patients with high clinical riska had Recurrence Score results 0–25 and may have been overtreated without the Recurrence Score result.2

High Clinical Risk Patients

Chemotherapy can potentially be spared

43% of patients with Recurrence Score results 26–100 had low clinical riska and may have been undertreated without the Recurrence Score result.2

Low Clinical Risk Patients

Chemotherapy can potentially be life-saving

a Low clinical risk defined by low grade and tumour size =3 cm, intermediate grade and tumour size =2 cm, and high grade and tumour size =1 cm; high clinical risk defined as all other cases with known values for grade and tumour size

Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.